Product Description
OQL036 is a novel topical agent that locally alleviates the toxicities induced by capecitabine metabolites, and reduces the inflammation associated with HFS. OnQuality aims to keep patients in cancer treatment and to improve their quality of life. (Sourced from: https://www.benzinga.com/pressreleases/23/04/n32089788/onquality-announces-fda-clearance-of-ind-application-for-oql036-for-the-prophylaxis-of-capecitabin)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OnQuality Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Cancer Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|